Drugs in pediatric ischemic stroke

Current Drug Targets

Volumn 13, Issue 7, 2012, Pages 917-924

  Bennett, Kimberly Statler ^a   Morita, Denise C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Pediatric; Stroke; Thrombolytic

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPARINIZATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MORTALITY; MOYAMOYA DISEASE; PRACTICE GUIDELINE; RECANALIZATION; RECURRENT DISEASE; REYE SYNDROME; RISK REDUCTION;

EID: 84861708889     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800675678     Document Type: Article

References (48)

1. Stroke in childhood: Clinical guidelines for diagnosis, management and rehabilitation2004: Available from: http://bookshop.rcplondon.ac.us/contents/f98c6540-a541-4bed-837d-ef293ac458bf.pdf, Accessed June 6, 2011.
2. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl): 887S-968S.
3. Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39: 2644-91.
4. Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the american heart association/american stroke association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the american academy of neurology affirms the value of this guideline as an educational tool for neurologists. stroke 2007; 38: 1655-711.
5. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39: 1647-52.
6. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP, Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-8.
7. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 227-76.
8. Ringleb PA, Bousser M-G, Ford G, et al. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 20082008: Available from: http://www.eso-stroke.org/pdf/ ESO%20Guidelines_update_Jan_2009.pdf, Accessed June 6, 2011.
9. Goldenberg NA, Bernard TJ, Fullerton HJ, Gordon A, deVeber G. Antithrombotic treatments, outcomes, and prognostic factors in acute childhood-onset arterial ischaemic stroke: a multicentre, observational, cohort study. Lancet neurology 2009; 8: 1120-7.
10. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2000(2):CD000024.
11. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-81.
12. Camerlingo M, Salvi P, Belloni G, et al. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 2005; 36: 2415-20.
13. Chamorro A, Busse O, Obach V, et al. The rapid anticoagulation prevents ischemic damage study in acute stroke--final results from the writing committee. Cerebrovasc Dis 2005; 19: 402-4.
14. Burak CR, Bowen MD, Barron TF. The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke. Pediatr Neurol 2003; 29: 295-8.
15. Beslow LA, Smith SE, Vossough A, et al. Hemorrhagic transformation of childhood arterial ischemic stroke. Stroke 2011; 42: 941-6.
16. Tissue plasminogen activator for acute ischemic stroke. the national institute of neurological disorders and stroke rt-pa stroke study group. N Engl J Med 1995; 333:1581-7.
17. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. national institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study group. N Engl J Med 1999; 340: 1781-7.
18. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
19. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55:1649-55.
20. Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010; 41: 288-94.
21. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
22. Brandt T, von Kummer R, Muller-Kuppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996; 27: 875-81.
23. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19: 1216-22.
24. Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 2006; 37: 922-8.
25. Arnold M, Steinlin M, Baumann A, et al. Thrombolysis in childhood stroke: report of 2 cases and review of the literature. Stroke 2009; 40: 801-7.
26. Benedict SL, Ni OK, Schloesser P, White KS, Bale JF, Jr. Intraarterial thrombolysis in a 2-year-old with cardioembolic stroke. J Child Neurol 2007; 22: 225-7.
27. Irazuzta J, Sullivan KJ. Hyperacute therapies for childhood stroke: a case report and review of the literature. Neurol Res Int 2010; 2010: 497326.
28. Jain SV, Morton LD. Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator. Pediatr Neurol 2008; 38: 126-9.
29. Modrau B, Sorensen L, Bartholdy NJ, et al. Systemic thrombolytic therapy alone and in combination with mechanical revascularization in acute ischemic stroke in two children. Case Rep Neurol 2011; 3: 91-6.
30. Amlie-Lefond C, deVeber G, Chan AK, et al. Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study. Lancet neurology 2009; 8: 530-6.
31. Janjua N, Nasar A, Lynch JK, Qureshi AI. Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample. Stroke 2007; 38: 1850-4.
32. Statler KD, Dong L, Nielsen DM, Bratton SL. Pediatric stroke: clinical characteristics, acute care utilization patterns, and mortality. Childs Nerv Syst 2011; 27: 565-73.
33. rd, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159: 1248-53.
34. Strater R, Kurnik K, Heller C, et al. Aspirin versus low-dose lowmolecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke 2001; 32: 2554-58.
35. Ganesan V, Prengler M, Wade A, Kirkham FJ. Clinical and radiological recurrence after childhood arterial ischemic stroke. Circulation 2006;114: 2170-7.
36. Schror K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs 2007;9: 195-204.
37. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
38. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
39. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
40. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-17.
41. Soman T, Rafay MF, Hune S, et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke 2006; 37: 1120-2.
42. Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation 2008; 117: 553-9.
43. The European Stroke Prevention Study (ESPS). Principal endpoints. The ESPS Group. Lancet 1987; 2: 1351-4.
44. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-16.
45. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
46. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51.
47. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136: 439-45.
48. Botting RM. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010; 62: 518-25.